Over the past decade, important progress in the treatment options for acromegaly has been made, which required an update of the 'Cortina criteria for cure' described in a consensus statement of ...

Patients with acromegaly require fortnightly or monthly ... requiring supervision and all 30 patients received adequate treatment throughout the study. Efficacy was similarly high in both groups ...

Meanwhile, some people might notice they can no longer tolerate the cold—which is one sign of hypothyroidism, or an underactive thyroid. The condition slows metabolism and triggers a drop in body ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

The NDA is supported by data from 18 clinical trials, including two Phase 3 trials that evaluated paltusotine for the treatment of acromegaly in medically untreated and treated patients.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA cleared a drug-free capsule for weight management ...

The NDA is supported by data from 18 clinical trials, including two Phase 3 trials that evaluated paltusotine for the treatment of acromegaly in medically untreated and treated patients.

For informational purposes only. Consult a medical professional for advice. Source: Focus Medica. A rare condition which results from excessive production of growth hormone by the pituitary gland ...

The company's lead candidate, paltusotine, is positioned to potentially become the first once-daily oral treatment for acromegaly, marking a significant milestone in the company's journey towards ...

The company's lead candidate, paltusotine, is positioned to potentially become the first once-daily oral treatment for acromegaly, marking a significant milestone in the company's journey towards ...